The oncogenic mutation V600E in BRAF protein accounts for 50%–60% of the somatic mutations in melanoma leading to constitutive activation of the protein kinase BRAF and downstream induction of the MAP kinase/ERK-signaling pathway with correlated melanomagenesis. Here, BRAF is linked to melanoma.